Optimizing MSP reaction conditions of MGMT promoter in glioblastoma FFPE samples
Abstract
Keywords
Full Text:
PDFReferences
Chen, R., Smith-Cohn, M., Cohen, A.L., Colman, H. 2017: Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics, 14:284-297 https://doi.org/10.1007/s13311-017-0519-x
Christians, A., Hartmann, C., Benner, A., Meyer, J., von Deimling, A., Weller, M., Wick, W., Weiler, M. 2012: Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One, 7(3):e33449 https://doi.org/10.1371/journal.pone.0033449
de Ruijter, T.C., de Hoon, J.P., Slaats, J., de Vries, B., Janssen, M.J., van Wezel, T., Aarts, M.J., van Engeland, M., Tjan-Heijnen, V.C., Van Neste, L., Veeck, J. 2015: Formalin-fixed, paraffin-embedded (FFPE) tissueepigenomics using Infinium HumanMethylation450BeadChip assays. Models and Techniques, 95:833-842(2015) https://doi.org/10.1038/labinvest.2015.53
Dietrich, D., Uhl, B., Sailer, V., Holmes, E.E., Jung, M., Meller, S., Kristiansen, G. 2013: Improved PCR Performance Using Template DNA from Formalin-Fixed and Paraffin-Embedded Tissues by Overcoming PCR Inhibition. PLoS One, 8(10):e77771. https://doi.org/10.1371/journal.pone.0077771
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S.N., Hidalgo, O.F., Vanaclocha, V., Baylin, S.B., Herman, J.G. 2000: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England journal of medicine, 343(19):1350-4 https://doi.org/10.1056/NEJM200011093431901
Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L., Paul, C.L., 1992: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proceedings of the National Academy of Sciences of the United States of America, 89(5):1827-1831 https://doi.org/10.1073/pnas.89.5.1827
Holmes, E.E., Jung, M., Meller, S., Leisse, A., Sailer, V., Zech, J., Mengdehl, M., Garbe, L.A., Uhl, B., Kristiansen, G., Dietrich, D. 2014: Performance Evaluation of Kits for Bisulfite-Conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. PLoS One, 9(4):e93933 https://10.1371/journal.pone.0093933
Kint, S., De Spiegelaere, W., De Kesel, J., Vandekerckhove, L., Van Criekinge, W. 2018: Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. PLoS One, 13(6): e0199091 https://doi.org/10.1371/journal.pone.0199091
Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W. 2016: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 131(6):803-20 https://doi.org/10.1007/s00401-016-1545-1
Ludgate, J.L., Wright, J., Stockwell, P.A., Morison, I.M., Eccles, M.R., Chatterjee, A. 2017: A streamlined method for analysing genome-wide DNA methylation patterns from low amounts of FFPE DNA. BMC medical genomics, 10(1):54 https://doi.org/10.1186/s12920-017-0290-1
Patterson, K., Molloy, L., Qu, W., Clark, S. 2011: DNA Methylation: Bisulphite Modification and Analysis. Journal of Visualized Experiments, (56):3170 https://doi.org/10.3791/3170
Sengüven, B., Baris, E., Oygur, T., Berktas, M. 2014: Comparison of methods for the extraction of DNA from formalin-fixed, paraffin-embedded archival tissues. International journal of medical sciences, 11(5):494-9 https://doi.org/10.7150/ijms.8842
Soomro, S.H., Ting, L.R., Qing, Y.Y., Ren, M. 2017: Molecular biology of glioblastoma: Classification and mutational locations . The Journal of the Pakistan Medical Association, 67(9):1410-1414
Thon, N., Eigenbrod, S., Grasbon-Frodl, E.M., Lutz, J., Kreth, S., Popperl, G., Belka, C., Kretzschmar, H.A., Tonn, J.C., Kreth, F,W. 2011: Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. Journal of neurology, neurosurgery, and psychiatry, 82(4):441–446 https://doi.org/10.1136/jnnp.2010.214593
Thon, N., Kreth, S., Kreth, F.W. 2013: Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets and therapy, 6:1363-72. https://doi.org/10.2147/OTT.S50208
Tournier, B., Chapusot, C., Courcet, E., Martin, L., Lepage, C., Faivre, J., Piard, F. 2012: Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method. BMC Cancer, 12:12 https://doi.org/10.1186/1471-2407-12-12
Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.D., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M, O’Kelly, M.,Temayo, P., Weir, B.A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, DN.; Cancer Genome Atlas Research Network. 2010: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1):98-110 https://doi.org/10.1016/j.ccr.2009.12.020
Refbacks
- There are currently no refbacks.